What Are Bausch Health’s Core Growth Drivers for Next Five Years?

Core growth drivers

Bausch Health (BHC) has categorized seven of its most promising assets, which involve both recently launched and commercialized products as well as late-stage pipeline products like the company’s “Significant Seven.” According to the company’s third-quarter earnings conference call, these products are expected to emerge as core growth drivers for Bausch Health in the next five years. According to the company’s third-quarter earnings presentation, these seven products, which contributed less than $100 million to the company’s revenues in 2017, are expected to report annualized peak revenues of over $1.0 billion over the next five years.

What Are Bausch Health’s Core Growth Drivers for Next Five Years?

Significant Seven

Relistor was approved by the FDA for opioid-induced constipation in July 2016 and launched in the US market in September 2016. According to the company’s third-quarter earnings conference call, oral Relistor has reported 88% YoY sales growth in 2018 YTD. According to the company’s third-quarter earnings presentation, the Relistor franchise also reported an 88% YoY rise in revenues in the third quarter due to the robust rise in sales volumes and improved net pricing.

Siliq was approved by the FDA for the plaque psoriasis indication in February 2017 and was launched in the US market in July 2017. Vyzulta was approved by the FDA in the open-angle glaucoma indication in November 2017 and was launched in the US market in December 2017. Lumify was approved by the FDA as an over-the-counter (or OTC) eyedrop for eye redness in December 2017 and launched in the US market in May 2018.

In September 2018, Bausch Health launched the Aqualox or SiHy daily lenses in Japan. According to the company’s third-quarter earnings presentation, Bausch Health expects to launch these lenses globally in future quarters.

In November 2018, Bausch Health secured FDA approval for its plaque psoriasis lotion, Bryhali. The Prescription Drug User Fee Act (or PDUFA) date for the new drug application of another psoriasis drug, DUOBRII, is set as February 15, 2019.